Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Sun Pharma sudden...

    Sun Pharma sudden closure of Vadodara RnD units leaves around 85 employees in lurch

    Farhat NasimWritten by Farhat Nasim Published On 2019-08-03T15:26:58+05:30  |  Updated On 13 Aug 2021 4:47 PM IST

    Mumbai: In a move that will axe job of around 85 employees (as pegged my market sources), Dilip Shanghvi led Sun Pharmaceuticals Ltd. (Sun Pharma) has decided to shut down two of its Research and Development (RnD) Units based in Vadodara.


    The move comes as a sudden shock to the employees, state medical reports as it comes without any prior intimation to the affected scientists.


    According to various media accounts, the closure of these units has come in a wake of stiff competition and pricing pressure confronted by the Indian generic firms in the US. In a bid to optimise operational cost, Sun Pharma after reviewing the available options concluded to discontinue operations at two Clinical Pharmacology Units located at Tandalja and Akota in Vadodara. The sub-optimal utilisation of these units was not cost-competitive.


    A clinical pharmacology unit (CPU) is dedicated to conducting early-phase clinical studies. Sun Pharma performs bio-equivalence studies at its in-house CPUs to facilitate the introduction of generics into the national and international markets. The company has 10 RnD units.


    Also Read: Sun Pharma to ramp up global speciality business; eyes "low-to-mid teens" growth in revenues for FY20


    The clinical research handled by the Vadodara facility will now be taken care of by the Gurgaon RnD centre, started by former Ranbaxy while the remaining research operations will continue at the Vadodara unit.


    On the other hand, the affected employees have reportedly been handed over a notice of dismissal along with three months advance salary as severance package. In addition to this, the company has stated that the employees who have been terminated from their services will be offered full support and the company will be helping them with outplacement services as well as that of a counsellor.


    Also Read: Sun Pharma former RnD head murders family of three, then commits suicide


    As per a media report by LiveMint, bouncers were allegedly called by the company to control the situation as the employees were informed about the discontinuation of services when they reported for work like usual. Responding to the allegation a Sun pharma spokesperson told the daily, "We also categorically deny that the company used the services of any bouncers as alleged in certain messages on social media."


    Confirming the development about closure, a Sun Pharma spokesperson told TOI, "While we continue to make investments in our RnD operations, we also constantly evaluate our resources and future capacity requirements to bring in efficiencies in cost and processes. To ensure optimal utilisation of clinical pharmacology units (CPUs) that conduct bio-equivalence studies, we are discontinuing operations at two centres at Tandalja and Akota, Vadodara. The bio-equivalence studies from these centres will be transferred to our other facilities. We are offering full support to the affected employees and helping them with outplacement services."


    All regulatory authorities have been updated about the same, ensuring compliance with all regulations, the company added. In FY19, the company's RnD spend (as a percentage of sales) had come down to 6.9 per cent from 8.6 per cent in the previous fiscal (FY18).

    AkotabouncersClinical Pharmacology UnitsCPUCPUsDilip Shanghvigeneric drugsGujaratGurgaonIndian drugmakerpharmapharma newspharma news indiaprice pressureRanbaxyResearchnDevelopmentSun PharmaSun pharma closureSun pharma cost cut plansun pharma employeesSun Pharma job cutSun Pharma RnD unitsSun Pharma salarySun PharmaceuticalsTandaljaUS drug priceVadodara.
    Source : with inputs

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok